

***Amendments to the Claims***

This listing of claims will replace all prior versions, and listings of claims in the application.

1-40. (cancelled)

41. (previously presented) An isolated peptide less than 15 amino acids in length comprising an oligopeptide selected from the group consisting of:

QAFTFSPTYK (SEQ ID NO:638);

LVVDFSQFSR (SEQ ID NO:620);

NVSIPWTHK (SEQ ID NO:625); and

SAICSVVRR (SEQ ID NO:653).

42. (withdrawn) The peptide of claim 41, wherein said peptide is 11 amino acids in length.

43. (previously presented) The peptide of claim 41, wherein said peptide is 10 amino acids in length.

44. (withdrawn) The peptide of claim 41, wherein said peptide is 9 amino acids in length, and wherein said oligopeptide is selected from the group consisting of:

NVSIPWTHK (SEQ ID NO:625); and

SAICSVVRR (SEQ ID NO:653).

45. (withdrawn) The peptide of claim 41, wherein said peptide is fused to a T helper peptide.

46. (previously presented) The peptide of claim 41, wherein said peptide is fused to spacer or linker amino acids.
47. (withdrawn) The peptide of claim 41, wherein said peptide is fused to a carrier.
48. (withdrawn) The peptide of claim 41, wherein said peptide is linked to a lipid.
49. (withdrawn) A fusion protein comprising the peptide of claim 41.
50. (withdrawn) A homopolymer of the peptide of claim 41.
51. (withdrawn) A heteropolymer of the peptide of claim 41 and a different peptide.
52. (previously presented) A composition comprising the peptide of claim 41 and a carrier.
53. (previously presented) A pharmaceutical composition comprising the peptide of claim 41 and a pharmaceutically acceptable carrier.
54. (withdrawn) A composition comprising the peptide of claim 41 and a liposome.
55. (currently amended) A composition comprising the peptide of claim 41 and one or more second peptides, wherein said one or more second peptides is a cytotoxic T cell (CTL)- inducing peptide or a helper T cell (HTL)-inducing peptide.
56. (withdrawn) The composition of claim 55, wherein said peptides form a fusion protein.
57. (previously presented) The composition of claim 55, further comprising a carrier.

58. (previously presented) A pharmaceutical composition comprising the composition of claim 55 and a pharmaceutically acceptable carrier.

59. (withdrawn) The composition of claim 55, wherein said peptides are fused by spacer or linker amino acids.

60 (new) The composition of claim 55, wherein said cytotoxic T cell (CTL)-inducing peptide is 15 amino acids or less in length.

61. (new) The composition of claim 55, wherein said helper T lymphocyte epitope comprises a pan-DR-binding epitope.

62. (new) The composition of claim 61, wherein said pan-DR-binding epitope comprises the peptide aKXVWANTLKAAa (SEQ ID NO:3877), wherein "X" is either cyclohexylalanine, phenylalanine, or tyrosine, and "a" is either D-alanine or L-alanine.